Factbox: Pharma Giants with Public Trump Drug Pricing Deals

Overview of the Agreement

In a significant move to address prescription drug pricing in the United States, former President Donald Trump secured agreements with 16 major pharmaceutical companies. These agreements aim to align U.S. prescription drug prices with those in other developed nations. In exchange, the companies received three-year exemptions from tariffs on drug imports.

The pharmaceutical companies have committed to what is known as “most-favored-nation” pricing. This means they will sell their drugs directly to consumers through a new government platform called TrumpRx.gov. Additionally, the companies have pledged billions of dollars in investments within the United States.

The Initial Letters and Agreements

Back in July, Trump sent letters to the leaders of 17 large pharmaceutical companies, demanding that they match the U.S. prices of their new drugs with the lowest prices offered in other developed nations. Out of these 17 companies, 16 publicly announced agreements with the government. Below are some of the key details of these deals:

Pfizer

Pfizer agreed to lower prescription drug prices for American patients, including discounts of up to 85% through TrumpRx.gov. The company stated that the majority of its primary care treatments and some select brands, such as the rheumatoid arthritis drug Xeljanz, dermatitis drug Eucrisa, and post-menopausal osteoporosis medicine Duavee, will be offered at average savings of 50%, which can be as high as 85%.

Johnson & Johnson

Johnson & Johnson agreed to lower drug prices for American patients, including through the TrumpRx.gov platform. However, specific terms of the agreement, such as revised drug prices or the list of covered medicines, were not disclosed.

AstraZeneca

AstraZeneca agreed to lower prescription drug prices for American patients, including discounts of up to 80% through the TrumpRx.gov platform.

Novo Nordisk

Novo Nordisk, a weight-loss drug maker, agreed to reduce prices for its semaglutide medicines, including Wegovy and Ozempic, for American patients through the government’s Medicare, Medicaid, and a direct-to-patient cash channel. Prices of Ozempic and Wegovy will fall from $1,000 and $1,350 per month, respectively, to $350 when purchased through TrumpRx. The company will also provide widely-used insulin products, including NovoLog and Tresiba, at $35 per month through TrumpRx.

Eli Lilly

Eli Lilly agreed to offer Medicare beneficiaries its obesity medicines Zepbound and orforglipron, branded as Foundayo, at no more than $50 per month, with additional discounts for self-pay patients through LillyDirect. The company will also offer Emgality, a migraine treatment, at $299 per pen, and Trulicity, a diabetes medicine, at $389 per month through TrumpRx.

AbbVie

AbbVie agreed to lower drug prices through Medicaid and expand direct-to-patient offerings via TrumpRx for medicines, including Humira and Synthroid.

Bristol Myers Squibb

Bristol Myers Squibb said it will provide its blockbuster blood-thinner Eliquis to Medicaid for free as part of its deal with the Trump administration. It also agreed to donate more than seven tons of active pharmaceutical ingredient for Eliquis.

Gilead Sciences

Gilead Sciences agreed to provide select medicines to treat HIV, hepatitis C, hepatitis B, and COVID-19 at a discounted price for Medicaid beneficiaries. It also agreed to price future medicines at parity with other key developed nations and make its hepatitis C treatment, Epclusa, available at a discounted cash price through TrumpRx and its own direct-to-patient program.

EMD Serono

EMD Serono, a unit of Merck KGaA, agreed to sell its fertility treatments, including Gonal-f, Ovidrel, and Cetrotide, directly to consumers with a combined discount of 84% off list price if three of them were used in IVF. It would also offer all new drugs launched in the U.S. at the prices it charges in other developed countries.

Merck

Merck agreed to sell its diabetes drugs Januvia, Janumet, and Janumet XR—set to face generic competition next year—directly to U.S. consumers at about 70% off list prices. If approved, its experimental cholesterol drug enlicitide will also be offered through direct-to-consumer channels, including TrumpRx.

Roche

Roche unit Genentech agreed to lower prices for many of its medicines under Medicaid comparable to those available in other wealthy countries. It also agreed to make its influenza medicines available through TrumpRx.gov and through its own direct-to-patient program.

Novartis

Novartis agreed to launch new drugs in the U.S. at prices comparable to other developed countries. It also agreed to make multiple sclerosis drug Mayzent as well as cancer drugs Rydapt and Tabrecta available through its direct-to-patient platform and TrumpRx.gov.

Amgen

Amgen added cholesterol drug Repatha at a monthly price of $239, migraine drug Aimovig, and arthritis treatment Amjevita at $299 a month to its direct-to-patient program, which is 60% to 80% off list price.

Sanofi

Sanofi agreed to offer lower-cost medicines via TrumpRx and other direct-to-patient platforms, with average savings of about 70% on treatments for infections, heart disease, and diabetes. It also agreed to align the Medicaid price of several medicines with those in other high-income countries.

GSK

GSK agreed to make most of its inhaled respiratory medicines and other drugs available to patients on a direct-to-patient platform with savings of up to 66%. It also agreed to lower the price of certain medicines in Medicaid and launch new drugs with a “more balanced pricing approach” across developed nations.

Boehringer Ingelheim

Boehringer Ingelheim agreed to make its medicines available through TrumpRx.gov at discounted prices.

Regeneron

Regeneron anticipated announcing a deal with the Trump administration “in the near future.” It is the sole company among 17 large pharmaceutical companies that received letters from President Donald Trump in July that has yet to sign such an agreement.